|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM160A2 |
Gene summary for FAM160A2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM160A2 | Gene ID | 84067 |
| Gene name | FHF complex subunit HOOK interacting protein 1B | |
| Gene Alias | C11orf56 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8N612 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84067 | FAM160A2 | LZE24T | Human | Esophagus | ESCC | 1.16e-10 | 4.05e-01 | 0.0596 |
| 84067 | FAM160A2 | P2T-E | Human | Esophagus | ESCC | 5.45e-21 | 1.70e-01 | 0.1177 |
| 84067 | FAM160A2 | P4T-E | Human | Esophagus | ESCC | 8.73e-05 | 1.26e-02 | 0.1323 |
| 84067 | FAM160A2 | P5T-E | Human | Esophagus | ESCC | 1.22e-11 | 6.00e-02 | 0.1327 |
| 84067 | FAM160A2 | P8T-E | Human | Esophagus | ESCC | 4.01e-13 | 7.89e-02 | 0.0889 |
| 84067 | FAM160A2 | P9T-E | Human | Esophagus | ESCC | 2.44e-02 | 1.90e-02 | 0.1131 |
| 84067 | FAM160A2 | P10T-E | Human | Esophagus | ESCC | 2.18e-17 | 1.53e-01 | 0.116 |
| 84067 | FAM160A2 | P11T-E | Human | Esophagus | ESCC | 1.01e-13 | 4.89e-01 | 0.1426 |
| 84067 | FAM160A2 | P12T-E | Human | Esophagus | ESCC | 8.20e-18 | 1.71e-01 | 0.1122 |
| 84067 | FAM160A2 | P15T-E | Human | Esophagus | ESCC | 1.55e-13 | 2.25e-01 | 0.1149 |
| 84067 | FAM160A2 | P16T-E | Human | Esophagus | ESCC | 6.60e-08 | 8.59e-02 | 0.1153 |
| 84067 | FAM160A2 | P17T-E | Human | Esophagus | ESCC | 5.08e-03 | 7.81e-02 | 0.1278 |
| 84067 | FAM160A2 | P20T-E | Human | Esophagus | ESCC | 4.50e-13 | 2.18e-01 | 0.1124 |
| 84067 | FAM160A2 | P21T-E | Human | Esophagus | ESCC | 1.04e-10 | 1.16e-01 | 0.1617 |
| 84067 | FAM160A2 | P22T-E | Human | Esophagus | ESCC | 2.08e-17 | 8.17e-02 | 0.1236 |
| 84067 | FAM160A2 | P23T-E | Human | Esophagus | ESCC | 2.75e-11 | 1.39e-01 | 0.108 |
| 84067 | FAM160A2 | P24T-E | Human | Esophagus | ESCC | 4.20e-05 | 5.68e-02 | 0.1287 |
| 84067 | FAM160A2 | P26T-E | Human | Esophagus | ESCC | 1.98e-11 | 1.50e-01 | 0.1276 |
| 84067 | FAM160A2 | P27T-E | Human | Esophagus | ESCC | 2.90e-13 | 1.90e-01 | 0.1055 |
| 84067 | FAM160A2 | P28T-E | Human | Esophagus | ESCC | 9.77e-19 | 3.94e-01 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM160A2 | SNV | Missense_Mutation | novel | c.575C>T | p.Ser192Leu | p.S192L | Q8N612 | protein_coding | deleterious(0) | benign(0.085) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM160A2 | SNV | Missense_Mutation | c.209N>A | p.Arg70His | p.R70H | Q8N612 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FAM160A2 | SNV | Missense_Mutation | rs867323964 | c.2936N>T | p.Ser979Leu | p.S979L | Q8N612 | protein_coding | deleterious_low_confidence(0) | benign(0.158) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM160A2 | SNV | Missense_Mutation | c.2567C>T | p.Ala856Val | p.A856V | Q8N612 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FAM160A2 | SNV | Missense_Mutation | c.2307C>G | p.Asn769Lys | p.N769K | Q8N612 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| FAM160A2 | SNV | Missense_Mutation | c.1499N>G | p.Asp500Gly | p.D500G | Q8N612 | protein_coding | deleterious(0.02) | possibly_damaging(0.879) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| FAM160A2 | SNV | Missense_Mutation | novel | c.1730N>C | p.Asp577Ala | p.D577A | Q8N612 | protein_coding | tolerated(0.51) | possibly_damaging(0.57) | TCGA-LD-A9QF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
| FAM160A2 | insertion | Frame_Shift_Ins | novel | c.72_73insGAAAAAA | p.Leu25GlufsTer10 | p.L25Efs*10 | Q8N612 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FAM160A2 | insertion | Nonsense_Mutation | novel | c.464_465insTTTGTCCAGACCTCTGTGGAGGAGATGATCGCCAGTACCGC | p.Thr157SerfsTer8 | p.T157Sfs*8 | Q8N612 | protein_coding | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD | ||
| FAM160A2 | SNV | Missense_Mutation | rs773161858 | c.1054N>A | p.Ala352Thr | p.A352T | Q8N612 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |